Unleash the power of precision with Nonacus
Enhanced sensitivity
Empower your genomic analysis with our advanced technology, enabling highly sensitive detection of low-frequency variants for precise and reliable results.
Versatile DNA sample compatibility with Cell3™ Target
Analyze all DNA sample types, from genomic DNA (gDNA) from fresh frozen tissue (FF), to cell-free DNA (cfDNA) and fixed formalin paraffin embedded tissue (FFPE), for versatile and comprehensive genetic testing.
Comprehensive sample-to-report solution with GALEAS™
Streamline your testing process with our complete sample-to-report solution, saving you valuable time while ensuring comprehensive and efficient genetic analysis.
Empowering precision medicine
Develop personalized and targeted treatment strategies through comprehensive genomic analysis, supporting close monitoring of treatment response and enabling early detection of disease recurrence for improved patient outcomes.
GALEAS™ - revolutionizing cancer diagnosis and monitoring
GALEAS™ revolutionises cancer management with its groundbreaking end-to-end solution. By leveraging the potential of liquid biopsies, GALEAS™ enables precise cancer diagnosis, continuous monitoring, and detection of minimal residual disease (MRD).
This transformative approach empowers healthcare professionals with comprehensive insights, ensuring accurate and actionable information for enhanced patient outcomes and personalised treatment strategies. Experience the power of GALEAS™ for a new era in cancer management.
Cell3™ Target technology- optimized performance for reliable variant calling
Cell3™ Target Technology is a groundbreaking innovation that ensures optimized performance, regardless of the size of the NGS panel. It is a versatile solution suitable for all DNA sample types, including gDNA and cfDNA, and DNA from FFPE and fresh frozen (FF) tissues.
The key feature of Cell3™ Target is its ability to confidently call variants down to 0.1% Variant Allele Frequency (VAF). This level of sensitivity enables accurate detection of low-frequency variants, essential for comprehensive genomic analysis.
Scientific recognition and proven validity
Our technology has achieved analytic and clinical validity as evidenced by publications in prestigious scientific journals such as Nature, Journal of Clinical Oncology, and Journal of Molecular Diagnostics.
